Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
Moodys
Fuji
Colorcon
Cerilliant
Dow
Chinese Patent Office
Cipla
Harvard Business School
Medtronic

Generated: January 23, 2018

DrugPatentWatch Database Preview

SELZENTRY Drug Profile

« Back to Dashboard

Which patents cover Selzentry, and what generic alternatives are available?

Selzentry is a drug marketed by Viiv Hlthcare and is included in two NDAs. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and forty-eight patent family members in fifty-nine countries.

The generic ingredient in SELZENTRY is maraviroc. There are two drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the maraviroc profile page.
Summary for SELZENTRY
Drug patent expirations by year for SELZENTRY
Pharmacology for SELZENTRY

US Patents and Regulatory Information for SELZENTRY

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Viiv Hlthcare SELZENTRY maraviroc TABLET;ORAL 022128-002 Aug 6, 2007 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Viiv Hlthcare SELZENTRY maraviroc SOLUTION;ORAL 208984-001 Nov 4, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Viiv Hlthcare SELZENTRY maraviroc TABLET;ORAL 022128-001 Aug 6, 2007 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Viiv Hlthcare SELZENTRY maraviroc TABLET;ORAL 022128-002 Aug 6, 2007 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Viiv Hlthcare SELZENTRY maraviroc TABLET;ORAL 022128-003 Nov 4, 2016 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Viiv Hlthcare SELZENTRY maraviroc SOLUTION;ORAL 208984-001 Nov 4, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Viiv Hlthcare SELZENTRY maraviroc TABLET;ORAL 022128-004 Nov 4, 2016 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Viiv Hlthcare SELZENTRY maraviroc TABLET;ORAL 022128-001 Aug 6, 2007 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Viiv Hlthcare SELZENTRY maraviroc TABLET;ORAL 022128-003 Nov 4, 2016 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Viiv Hlthcare SELZENTRY maraviroc TABLET;ORAL 022128-001 Aug 6, 2007 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for SELZENTRY
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Tablets 150 mg and 300 mg ➤ Subscribe 8/8/2011

Non-Orange Book US Patents for SELZENTRY

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,503,905 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives ➤ Subscribe
6,586,431 3,3-Biarylpiperidine and 2,2-biarylmorpholine derivatives ➤ Subscribe
7,041,667 CCR5 modulators ➤ Subscribe
7,217,714 CCR5 modulators ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for SELZENTRY

Supplementary Protection Certificates for SELZENTRY

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0338 Netherlands ➤ Subscribe
417 Luxembourg ➤ Subscribe 91417, EXPIRES: 20220918
C008/2008 Ireland ➤ Subscribe SPC008/2008: 20081105, EXPIRES: 20220917
C0007 France ➤ Subscribe PRODUCT NAME: MARAVIROC; REGISTRATION NO/DATE: EU/1/07/418/001 20070918
2008 Austria ➤ Subscribe PRODUCT NAME: MARAVIROC, GEGEBENENFALLS IN DER FORM EINES PHARMAZEUTISCH VERTRAEGLICHEN SALZES; REGISTRATION NO/DATE: EU/1/07/418/001-010 20070918
2008004,C1284974 Lithuania ➤ Subscribe PRODUCT NAME: MARAVIROCUM; REGISTRATION NO/DATE: EU/1/07/418/001 - EU/1/07/418/010 20070918
2008000011 Germany ➤ Subscribe PRODUCT NAME: 4,4-DIFLUORO-N-((1S)-3-((1R,3S,5S)-3-(3-METHYL-5-(PROPAN-2-YL)-4H-1,2,4-TRIAZOL-4-YL)-8-AZABICYCLO(3.2.1)OCTAN-8-YL)-1-PHENYLPROPYL)CYCLOHEXANECARBOXAMIDE; REGISTRATION NO/DATE: EU/1/07/418/001-010 20070918
1284974/01 Switzerland ➤ Subscribe FORMER OWNER: PFIZER INC., US
00338 Netherlands ➤ Subscribe PRODUCT NAME: MARAVIROC, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/07/418/001-010 20070918
2008 00018 Denmark ➤ Subscribe PRODUCT NAME: MARAVIROC, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Healthtrust
Deloitte
Chinese Patent Office
McKinsey
Harvard Business School
Cantor Fitzgerald
Fuji
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot